The Clinical Role of Intravenous Glutamine in Trauma Patients Receiving Enteral Nutrition (GLINT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01240291|
Recruitment Status : Unknown
Verified May 2012 by Ruqaiya Al-Balushi, Royal Brisbane and Women's Hospital.
Recruitment status was: Recruiting
First Posted : November 15, 2010
Last Update Posted : May 24, 2012
|Condition or disease||Intervention/treatment||Phase|
|Multiple Trauma Critically Ill||Dietary Supplement: Dipeptiven Dietary Supplement: normal saline||Phase 3|
Trauma Patients are characterized by alteration in the immune response, increased exposure to infectious complications, sepsis, and consequently organ failure and death. Glutamine supplementation to parenteral nutrition is one of the nutritional interventions that have been proven to be associated with improved survival rate, decreased infectious morbidity, costs, intensive care unit, and hospital length of stay. However, glutamine supplementation in patients receiving enteral nutrition and its best route are still controversial. A number of trials investigated the beneficial effects of intravenous alanyl-glutamine supplementation in critically ill patients receiving enteral nutrition. However, these trials were: pilot trials, investigated surrogate outcomes, or supplementation was for a short period of time. Therefore, a well designed trial is needed to investigate the effect of intravenous alanyl-glutamine supplementation in critically ill patients with multiple trauma receiving enteral nutrition on major clinical outcomes.
Our hypothesis is that trauma patients receiving standard enteral nutrition supplemented with intravenous alanyl-glutamine will demonstrate improved clinical outcomes compared to patients receiving standard enteral nutrition without supplementation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||88 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Intravenous GLutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomized, Placebo-controlled Clinical Trial|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||June 2013|
Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
Dietary Supplement: Dipeptiven
Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
Other Name: Fresenius Kabi
Placebo Comparator: normal saline
Intravenous placebo (normal saline; 0.9 %)
Dietary Supplement: normal saline
0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
Other Name: NaCl
- The change in daily total Sequential Organ Failure Assessment Score (SOFA)each day over 10 days. [ Time Frame: daily until discharge from intensive care unit, death or maximum duration of 10 days. ]The change in daily total SOFA score plotted each day over 10 days, where we will compare the regression slope between the two arms of the study.
- The change in daily total Sequential Organ failure Assessment Score (SOFA) on the last day of treatment as a measure of severity of organ dysfunction. [ Time Frame: Last day of treatment ]
- Number of infections that are documented during intensive care unit stay. [ Time Frame: During intensive care unit stay. ]
- Number of deaths occuring on or before day 60. [ Time Frame: within 60 days. ]
- Length of stay in intensive care unit. [ Time Frame: At discharge from intensive care unit. ]
- Length of stay in hospital. [ Time Frame: At hospital discharge. ]Length of stay in hospital (if delayed discharge due to placement problems, will record from the date the patient is regarded as fit for discharge by medical staff).
- Number of days on mechanical ventilation. [ Time Frame: during intensive care unit stay. ]
- Number of days of antibiotic use during intensive care unit stay. [ Time Frame: during intensive care unit stay. ]
- Fat free mass and fat percentage as a measure of body composition by Bioelectric Impedance analysis (BIA). [ Time Frame: every 2 days until discharge from the intensive care unit. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240291
|Contact: Ruqaiya M Al-Balushi, MSc||+ 61 7 3346 firstname.lastname@example.org|
|Contact: Jennifer Paratz, PhD||+ 61 7 email@example.com|
|Royal Brisbane & Women's Hospital||Recruiting|
|Brisbane, Queensland, Australia, 4029|
|Principal Investigator:||Jeffrey Lipman, MBBCh, MD||Royal Brisbane & Women's Hpsoital|